These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 25110869)
1. Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group. Tadmor T; Shvidel L; Bairey O; Goldschmidt N; Ruchlemer R; Fineman R; Rahimi-Levene N; Herishanu Y; Yuklea M; Arad A; Aviv A; Polliack A; Am J Hematol; 2014 Nov; 89(11):E218-22. PubMed ID: 25110869 [TBL] [Abstract][Full Text] [Related]
2. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082 [TBL] [Abstract][Full Text] [Related]
3. Survival of patients with transformed lymphoma in the rituximab era. Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374 [TBL] [Abstract][Full Text] [Related]
4. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056 [TBL] [Abstract][Full Text] [Related]
5. Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Tadmor T; Shvidel L; Goldschmidt N; Ruchlemer R; Fineman R; Bairey O; Rahimi-Levene N; Herishanu Y; Yuklea M; Arad A; Aviv A; Polliack A Anticancer Res; 2014 Feb; 34(2):785-90. PubMed ID: 24511013 [TBL] [Abstract][Full Text] [Related]
6. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N; Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720 [TBL] [Abstract][Full Text] [Related]
8. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature. Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963 [TBL] [Abstract][Full Text] [Related]
9. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Dalia S; Chavez J; Little B; Bello C; Fisher K; Lee JH; Chervenick P; Sokol L; Sotomayor E; Shah B Ann Hematol; 2014 Aug; 93(8):1305-12. PubMed ID: 24590536 [TBL] [Abstract][Full Text] [Related]
10. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
11. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077 [TBL] [Abstract][Full Text] [Related]
12. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484 [TBL] [Abstract][Full Text] [Related]
13. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661 [TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758 [TBL] [Abstract][Full Text] [Related]
16. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296 [TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967 [TBL] [Abstract][Full Text] [Related]
18. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era. Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292 [TBL] [Abstract][Full Text] [Related]